Table 2.
Mitophagy and AD biomarkers in CSF and serum.
| Memory Clinic Cohort |
P-values |
||||||
|---|---|---|---|---|---|---|---|
| All patients | AD Dementia | AD-MCI Patients | CU Controls | AD-MCI vs. ADDementia | AD MCIvs. CU | AD Dementiavs. CU | |
| Mitophagy biomarkers | N = 200 | N = 100 | N = 100 | N = 46 | |||
| CSF PINK1 ng/mL | 1.2 (0.2) | 1.3 (0.2) | 1.1 (0.2) | 1.0 (0.3) | <0.001 | 0.09 | <0.001 |
| Serum PINK1, ng/mL | 4.8 (10.7) | 6.4 (13.3) | 3.2 (6.8) | 5.1 (10.1) | 0.01 | 0.21 | 0.73 |
| Serum BNIP3L, ng/mL | 2.5 (1.8) | 2.9 (2.1) | 2.1 (1.2) | 2.7 (2.2) | 0.02 | 0.48 | 0.60 |
| Serum TFEB, pg/mL | 705.0 (361.8) | 670.1 (368.6) | 744.3 (351.9) | 966.5 (1562.5) | 0.03 | 0.90 | 0.04 |
| AD biomarkers | |||||||
| CSF Aβ42/40 | 0.04 (0.02) | 0.04 (0.01) | 0.04 (0.02) | 0.09 (0.02) | 0.74 | <0.001 | <0.001 |
| CSF Aβ42, pg/mL | 486.5 (187.2) | 493.0 (203.2) | 480.0 (170.5) | 1138.8 (474.7) | 0.99 | <0.001 | <0.001 |
| CSF t-MAPT/tau, pg/mL | 618.8 (409.2) | 667.3 (465.0) | 570.9 (341.3) | 225.5 (113.1) | 0.17 | <0.001 | <0.001 |
| CSF p-MAPT/tau (181), pg/mL | 101.9 (65.7) | 107.4 (69.6) | 96.4 (61.5) | 37.2 (17.6) | 0.29 | <0.001 | <0.001 |
| Serum NEFL pg/mL | 35.342 (26.4) | 38.7 (21.0) | 35.8 (31.2) | 14.0 (5.6) | 0.10 | <0.001 | <0.001 |
| CSF NEFL pg/mL | 1293.0 (910.3) | 1571.2 (979.8) | 1304.2 (864.1) | 666.1 (455.3) | 0.04 | <0.001 | <0.001 |
| CSF NRGN, pg/mL | 253.7 (103.8) | 267.3 (107.8) | 253.8 (101.6) | 188.2 (70.8) | 0.77 | 0.03 | 0.01 |
Data are presented as N (%) and mean (SD) unless otherwise specified.
P values are comparisons using Tukey post hoc tests (one-way analysis of covariance was used to test the main between group differences), adata were log-tranformed.
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease; CU, cognitively unimpaired; CSF, cerebrospinal fluid; NEFL, neurofilament light chain; NRGN, neurogranin.